Skip to main content
AL

Arthur L. Burnett

Biography​

Arthur L. Burnett is the Patrick C. Walsh Professor of Urology at Johns Hopkins School of Medicine and directs its Sexual Medicine Fellowship Program.1 He received his medical degree from Johns Hopkins University School of Medicine and completed urology residency and fellowship training at The Johns Hopkins Hospital.2 He has served as president of the Sexual Medicine Society of North America.3

Contributions​

Burnett's cited work covers erectile dysfunction evaluation and treatment, including an AUA guideline and a systematic review of penile prosthesis survival. His priapism papers examine prevention of recurrent ischemic priapism with phosphodiesterase type 5 inhibitors and a corporoglanular shunt modification called the corporal "snake" maneuver.45678

Cited on WARWIKI

20 publications with Arthur L. Burnett as a listed author are cited on WARWIKI, ordered by the number of pages that cite them. Papers whose author list is shortened to "et al." before this name are not included.

  1. Burnett AL, Nehra A, Breau RH, et al. "Erectile dysfunction: AUA guideline." J Urol. 2018;200(3):633–641. doi
    Cited on: Platelet-Rich Plasma (PRP) · Intracavernosal Injection Agents · Intraurethral Alprostadil
  2. Pereira DA, Calmasini FB, Costa FF, Burnett AL, Silva FH. Nitric oxide resistance in priapism associated with sickle cell disease: mechanisms, therapeutic challenges, and future directions. J Pharmacol Exp Ther. 2024;390:203–212. doi
    Cited on: Priapism Management — Pharmacologic Agents · Priapism
  3. Hou LT, Burnett AL. Regimented Phosphodiesterase Type 5 Inhibitor Use Reduces Emergency Department Visits for Recurrent Ischemic Priapism. J Urol. 2021;205(2):545-553. doi
    Cited on: PDE5 Inhibitors · Priapism Management — Pharmacologic Agents
  4. Burnett AL, et al. Randomized controlled trial of sildenafil for preventing recurrent ischemic priapism in sickle cell disease. Am J Med. 2014;127:664–668. doi
    Cited on: PDE5 Inhibitors · Priapism Management — Pharmacologic Agents
  5. Burnett AL, Bivalacqua TJ, Champion HC, et al. Feasibility of the use of phosphodiesterase type 5 inhibitors in a pharmacologic prevention program for recurrent priapism. J Sex Med. 2006;3(6):1077-1084. doi
    Cited on: PDE5 Inhibitors · Priapism Management — Pharmacologic Agents
  6. Bhasin S, Burnett AL, Gagliano-Jucá T, et al. Testosterone Treatment in Prostate Cancer Survivors With Hypogonadism: A Randomized Clinical Trial. JAMA Intern Med. 2026;186(7):805-814. doi
    Cited on: Cancer Survivorship
  7. Capogrosso P, Albersen M, Burnett AL, et al. Erectile dysfunction: update on clinical management. Eur Urol. 2025;88(4):388–399. doi
    Cited on: Erectile Dysfunction (Procedures)
  8. Maremanda AP, Du Comb W, Able C, Kohn TP, Unal S, Burnett AL. Erectile dysfunction and Peyronie's disease diagnosis rates after penile fracture — a retrospective claims database cohort analysis. Int J Impot Res. 2024;36(2):125–128. doi
    Cited on: Penile Fracture
  9. Unal S, Karakus S, Du Comb W, Burnett AL. Clinical outcomes of the Burnett "snake" maneuver shunt modification for ischemic priapism. J Sex Med. 2024;21(8):723-728. doi
    Cited on: Priapism Shunts & Decompression
  10. Idris IM, Burnett AL, DeBaun MR. Epidemiology and treatment of priapism in sickle cell disease. Hematology Am Soc Hematol Educ Program. 2022;2022(1):450–458. doi
    Cited on: Priapism
  11. Miller LE, Khera M, Bhattacharyya S, Patel M, Nitschelm K, Burnett AL. Long-term survival rates of inflatable penile prostheses: systematic review and meta-analysis. Urology. 2022;166:6–10. doi
    Cited on: Penile Implants
  12. Haney NM, Huang MM, Liu JL, Hawksworth DJ, Burnett AL. Acellular dermal matrix tissues in genitourinary reconstructive surgery: a review of the literature and case discussions. Sex Med Rev. 2021;9:488–497. doi
    Cited on: Human Acellular Dermal Matrix

Footnotes​

  1. Sexual Medicine and Reconstructive Urology Fellowship. Accessed October 2026. ↩

  2. Dr. Arthur Burnett, MD. Urology. Accessed October 2026. ↩

  3. Dr. Arthur Burnett |. Accessed October 2026. ↩

  4. Burnett AL, Nehra A, Breau RH, et al. "Erectile dysfunction: AUA guideline." J Urol. 2018;200(3):633–641. doi:10.1016/j.juro.2018.05.004 ↩

  5. Hou LT, Burnett AL. Regimented Phosphodiesterase Type 5 Inhibitor Use Reduces Emergency Department Visits for Recurrent Ischemic Priapism. J Urol. 2021;205(2):545-553. doi:10.1097/ju.0000000000001365 ↩

  6. Burnett AL, et al. Randomized controlled trial of sildenafil for preventing recurrent ischemic priapism in sickle cell disease. Am J Med. 2014;127:664–668. doi:10.1016/j.amjmed.2014.03.019 ↩

  7. Burnett AL, Bivalacqua TJ, Champion HC, et al. Feasibility of the use of phosphodiesterase type 5 inhibitors in a pharmacologic prevention program for recurrent priapism. J Sex Med. 2006;3(6):1077-1084. doi:10.1111/j.1743-6109.2006.00333.x ↩

  8. Burnett AL, Anele UA, Trueheart IN, Strouse JJ, Casella JF. Randomized controlled trial of sildenafil for preventing recurrent ischemic priapism in sickle cell disease. Am J Med. 2014;127:664–668. doi:10.1016/j.amjmed.2014.03.019 ↩